N,N'-乙基二-L-半胱氨酸 | 14344-48-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 半胱氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N'-乙基二-L-半胱氨酸
• 英文名称: N,N'-ethylenebis(L-cysteine)
• 英文别名: N,N'-ethylenedi-L-cysteine；ethylelebis(L-cysteine)；ethylene-bis-L-cysteine；ethylenedicysteine；(D,L)-N,N'-1,2-ethylenediylbiscysteine；N,N'-(1,2-ethanediyl)-bis-L-cysteine；(2R)-2-[2-[[(1R)-1-carboxy-2-sulfanylethyl]amino]ethylamino]-3-sulfanylpropanoic acid
• CAS: 14344-48-0
• 化学式: C₈H₁₆N₂O₄S₂
• 分子量: 268.358
• InChiKey: BQHFYSWNHZMMDO-WDSKDSINSA-N

物化性质

• 熔点：
  245-246℃
• 密度：
  1.366

计算性质

• 辛醇/水分配系数(LogP)：
  -5.4
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  101
• 氢给体数：
  6
• 氢受体数：
  8

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  N,N'-乙基二-L-半胱氨酸 在 sodium hydroxide 、 sodium 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 氨 、 水 为溶剂， 反应 2.5h， 生成 S,S'-bis-benzyl-N,N'-bis-benzyloxycarbonyl ethylene-bis-L-cysteine
  参考文献：
  名称：

  Synthesis and evaluation of β-homocysteine derivatives of99mTc-L,L-EC and99mTc-L,L-ECD

  摘要：

  Bis-amine bis-thiol tetraligands such as ethylene dicysteine (EC) and its diethylester (ECD) bind Tc-99m efficiently at room temperature and neutral to alkaline pH to form stable complexes. The use of bis-amine bis-thiol ligands as bifunctional chelating agents (BCAs) for labelling of bioactive compounds (peptides, diphosphonates, etc.) looks promising. To study the effect of extending the carboxylic side-group in Tc-99m-L,L-EC and Tc-99m-L,L-ECD, we have synthesised ethylene bis-L-beta-homocysteine (L,L-EC) and its diethylester derivative L,L-EhCD, incorporating a methylene group between each of the carboxyl groups and the N2S2 tetraligand core. The more distant carboxyl groups could offer reduced steric hindrance in the use of L,L-EhC and L,L-EhCD as BCAs.

  DOI：

  10.1002/(sici)1099-1344(199907)42:7<683::aid-jlcr230>3.0.co;2-0
• 作为产物：
  描述：

  L-噻唑烷-4-羧酸 在 sodium 、 氯化铵 作用下， 以 氨 为溶剂， 以23%的产率得到N,N'-乙基二-L-半胱氨酸
  参考文献：
  名称：

  EP1486216

  摘要：

  公开号：

文献信息

• CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING
  申请人：Reiley Pharmaceuticals, Inc.

  公开号：US20150374858A1

  公开（公告）日：2015-12-31

  Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

  披露了来自非甾体抗炎药（NSAIDs）的衍生物及其使用方法，这对于识别和定位患者疼痛感觉的病理和/或炎症部位；识别原发、继发、良性或恶性肿瘤的部位；以及诊断感染或确认或排除疑似感染非常有用。基于NSAID的偶联物含有成像基团。这些偶联物在环氧化酶表达增加的部位富集，从而揭示了前列腺素产生增加的部位，这与疼痛和炎症有关，并与肿瘤存在和/或位置有关。识别COX表达增加的区域也有助于筛查感染。
• Compositions and Methods for Cellular Imaging and Therapy
  申请人：Yang J. David

  公开号：US20070248537A1

  公开（公告）日：2007-10-25

  The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N 4 compounds and derivatives.

  本发明一般涉及化学和放射性核素成像领域。更具体地，涉及涉及N4化合物及其衍生物的成分、试剂盒和成像和治疗方法。
• [EN] A KIT FOR PREPARING A RADIOPHARMACEUTICAL<br/>[FR] NÉCESSAIRE DE PRÉPARATION D'UN PRODUIT RADIOPHARMACEUTIQUE
  申请人：SOUTH AFRICAN NUCLEAR ENERGY

  公开号：WO2015118498A1

  公开（公告）日：2015-08-13

  The present invention relates to a stabilized kit for the preparation of a radiopharmaceutical. In particular, the present invention relates to the use of a non-aqueous solvent for the stabilisation of the ligand component of the kit.

  本发明涉及一种用于制备放射性药物的稳定试剂盒。具体而言，本发明涉及使用非水溶剂来稳定试剂盒中的配体组分。
• APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES
  申请人：Indrevoll Bard

  公开号：US20130189186A1

  公开（公告）日：2013-07-25

  The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

  本发明涉及体内凋亡的放射性药物成像。该发明提供了靶向凋亡细胞的成像剂，通过选择性结合到暴露在凋亡细胞表面的氨基磷脂磷脂醇胺（PE）。这些放射性药物包括PE结合肽的螯合物共轭物的放射金属络合物。还提供了体内成像的药物组合物、试剂盒和方法。
• Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
  申请人：Board of Regents, The University of Texas System

  公开号：US20040166058A1

  公开（公告）日：2004-08-26

  The invention provides, in a general sense, a new labeling strategy employing compounds that are are N 2 S 2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, COX-2, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.

  该发明提供了一种新的标记策略，采用将N2S2螯合物与靶向配体结合的化合物，其中靶向配体是疾病细胞周期靶向化合物、肿瘤血管生成靶向配体、肿瘤凋亡靶向配体、疾病受体靶向配体、氨基磷酸酯、抗血管生成素、单克隆抗体C225、单克隆抗体CD31、单克隆抗体CD40、卡培他滨、COX-2、脱氧胞苷、富勒烯、赫塞汀、人血清白蛋白、乳糖、黄体生成激素、吡ridoxal、喹唑啉、沙利度胺、转铁蛋白或三甲基赖氨酸。本发明还涉及使用感兴趣的化合物的试剂盒，以及利用本发明化合物评估感兴趣药剂的药理学方法。